Shao-Lee Lin, Acelyrin CEO
Backed by Sean Harper and Beth Seidenberg, an LA biotech scores a massive $250M crossover ahead of 2022 IPO
When Acelyrin closed its Series A late last year, it was met with little fanfare. The biotech had only two employees, the former R&D chief …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
